Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Effective translation of breakthrough discoveries into innovative products in the clinic requires proactive mitigation or elimination of several drug development challenges. These challenges can vary depending upon the type of drug molecule. In the case of therapeutic antibody candidates, a commonly encountered challenge is high viscosity of the concentrated antibody solutions. Concentration-dependent viscosity behaviors of mAbs and other biologic entities may depend on pairwise and higher-order intermolecular interactions, non-native aggregation, and concentration-dependent fluctuations of various antibody regions. This article reviews our current understanding of molecular origins of viscosity behaviors of antibody solutions. We discuss general strategies and guidelines to select low viscosity candidates or optimize lead candidates for lower viscosity at early drug discovery stages. Moreover, strategies for formulation optimization and excipient design are also presented for candidates already in advanced product development stages. Potential future directions for research in this field are also explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A recombinant human enzyme for enhanced interstitial transport of therapeutics
Bookbinder, L. H., Hofer, A., Haller, M. F., Zepeda, M. L., Keller, G.-A., Lim, J. E., Edgington, T. S., Shepard, H. M., Patton, J. S., & Frost, G. I. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.027 · Cited by 282
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144 · cited 1×
“During downstream ultrafiltration and diafiltration steps, high viscosity of the antibody solution may increase the back pressure of the pump and decrease the transmembrane flux, which may increase the processing time, destabilize the drug substance and increase manufacturing costs.(14,15)”
BackgroundSelf-citation
Cited by
Mason, D. M., Friedensohn, S., Weber, C. R., Jordi, C., Wagner, B., Meng, S. M., Ehling, R. A., Bonati, L., Dahinden, J., Gainza, P., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00699-9 · Cited by 308
Predicting antibody developability profiles through early stage discovery screening
Bailly, M., Mieczkowski, C., Juan, V., Metwally, E., Tomazela, D., Baker, J., Uchida, M., Kofman, E., Raoufi, F., Motlagh, S., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1743053 · Cited by 228
Computational approaches to therapeutic antibody design: established methods and emerging trends
Norman, R. A., Ambrosetti, F., Bonvin, A. M. J. J., Colwell, L. J., Kelm, S., Kumar, S., & Krawczyk, K. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz095 · Cited by 219
Self-citationLai, P.-K., Gallegos, A., Mody, N., Sathish, H. A., & Trout, B. L. (2022) · mAbs · doi:10.1080/19420862.2022.2026208 · Cited by 103
Computational Procedure for Predicting Excipient Effects on Protein–Protein Affinities
Dignon, G. L., & Dill, K. A. (2024) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c01197 · Cited by 5
Metadata
- Authors
- Tomar, D. S., Kumar, S., Singh, S. K., Goswami, S., & Li, L.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2016-01-06
- Volume
- 8
- Issue
- 2
- Pages
- 216-228
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2229692518
- Cited by
- 214
- References
- 2
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development. https://app.cochat.ai/papers/10.1080/19420862.2015.1128606
- The paper
- Tomar, D. S., Kumar, S., Singh, S. K., Goswami, S., & Li, L. (2016). Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development. mAbs. https://doi.org/10.1080/19420862.2015.1128606
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.